Disposition of 14413 shares by Mainolfi Nello of Kymera Therapeutics at 2.08 subject to Rule 16b-3
| KYMR Stock | USD 44.36 0.13 0.29% |
Slightly above 55% of Kymera Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Kymera Therapeutics suggests that many traders are impartial. Kymera Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Kymera Therapeutics. Many technical investors use Kymera Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Kymera |
Filed transaction by Kymera Therapeutics Director, Officer: Chief Executive Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Kymera Therapeutics Fundamental Analysis
We analyze Kymera Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kymera Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kymera Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Kymera Therapeutics is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Kymera Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kymera Therapeutics stock to make a market-neutral strategy. Peer analysis of Kymera Therapeutics could also be used in its relative valuation, which is a method of valuing Kymera Therapeutics by comparing valuation metrics with similar companies.
Peers
Kymera Therapeutics Related Equities
| PRLD | Prelude Therapeutics | 7.02 | ||||
| STTK | Shattuck Labs | 3.57 | ||||
| CGEM | Cullinan Oncology | 0.48 | ||||
| GLUE | Monte Rosa | 0.36 | ||||
| NRIX | Nurix Therapeutics | 0.15 | ||||
| RVMD | Revolution Medicines | 0.36 | ||||
| EWTX | Edgewise Therapeutics | 0.52 | ||||
| IPSC | Century Therapeutics | 1.10 | ||||
| AGIO | Agios Pharm | 2.60 | ||||
| MLYS | Mineralys Therapeutics, | 2.83 | ||||
| CCCC | C4 Therapeutics | 2.94 | ||||
| FHTX | Foghorn Therapeutics | 7.31 |
Additional Tools for Kymera Stock Analysis
When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.